sofosbuvir + velpatasvir + voxilaprevir at a glance
Medicine class
Pangenotypic direct-acting antiviral combination.
Licensed population
People aged 12 years or older who weigh at least 30 kg and have chronic hepatitis C.
Administration
Swallow whole with food; do not chew or crush because the tablet is bitter.
Specialist oversight
Treatment should be started and monitored by a clinician experienced in hepatitis C care.
What is sofosbuvir + velpatasvir + voxilaprevir used for?
Its UK licence covers:
Treatment of chronic hepatitis C virus infection in people aged 12 years or older who weigh at least 30 kg.
Use across hepatitis C genotypes, including in people with previous direct-acting antiviral exposure, where liver function and other clinical factors are suitable.
How does sofosbuvir + velpatasvir + voxilaprevir work?
Sofosbuvir stops the NS5B polymerase from copying viral RNA. Velpatasvir blocks NS5A, needed for viral replication and assembly, while voxilaprevir blocks the NS3/4A protease needed to process viral proteins. Together, these actions suppress hepatitis C replication.
sofosbuvir + velpatasvir + voxilaprevir preparations and strengths
Tablet
Route: Oral
Strengths: 400 mg + 100 mg + 100 mg
How to take sofosbuvir + velpatasvir + voxilaprevir
Follow the specialist team's instructions.
Take the tablet with food.
Swallow it whole; do not split, chew or crush it.
Tell the treatment team about prescription medicines, non-prescription products and herbal remedies before starting anything new.
sofosbuvir + velpatasvir + voxilaprevir side effects
Common or expected effects
- Headache
- Diarrhoea
- Nausea
- Abdominal pain
- Reduced appetite
- Vomiting
- Rash
- Muscle pain
- Raised bilirubin on blood testing
Get urgent medical advice
- Swelling of the face, lips, tongue or throat, suggesting angioedema
- A widespread severe rash with peeling skin or blisters involving the mouth, eyes or genitals
- Severe slowing of the heartbeat or heart block, particularly with current or recent amiodarone
sofosbuvir + velpatasvir + voxilaprevir in pregnancy
Human pregnancy information is limited. The combination is not recommended during pregnancy as a precaution. Discuss pregnancy, suspected pregnancy or plans to conceive promptly with the hepatitis specialist or prescriber.
sofosbuvir + velpatasvir + voxilaprevir while breastfeeding
It is unknown how much of the active substances enters human milk, and a risk to the infant cannot be excluded. The product should not be used while breastfeeding; feeding and treatment options require specialist discussion.
sofosbuvir + velpatasvir + voxilaprevir interactions
A complete interaction check is essential because some combinations are contraindicated or may reduce antiviral effectiveness.
Carbamazepine, phenobarbital or phenytoin
Strong induction can substantially reduce antiviral exposure; concomitant use is contraindicated.
Rifampicin or rifabutin
These can substantially reduce antiviral exposure; concomitant use is contraindicated.
St John’s wort
It can reduce antiviral concentrations and must not be taken with this combination.
Common questions about sofosbuvir + velpatasvir + voxilaprevir
Answers are fully visible for fast scanning and source review.
What is sofosbuvir + velpatasvir + voxilaprevir used for?
It treats chronic hepatitis C in licensed adolescents and adults. Specialists may select it when previous direct-acting antiviral treatment has not cleared the infection.
How does sofosbuvir + velpatasvir + voxilaprevir differ from sofosbuvir + velpatasvir?
It adds voxilaprevir, which blocks the viral NS3/4A protease, alongside NS5B and NS5A inhibition.
Does sofosbuvir + velpatasvir + voxilaprevir need to be taken with food?
Yes. The tablet should be swallowed whole with food.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.